ROIV and IMVT Related Headlines
Go Back- Immunovant halts CLE development after IMVT-1402 trial misses goal
- Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
- Immunovant posts $153M net loss as R&D spending climbs in fiscal Q1
- Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
- Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
- Bernstein SocGen Group Starts Immunovant (IMVT) at Market Perform
- Bernstein SocGen Group Starts Roivant Sciences (ROIV) at Outperform
- Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
- Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
ROIV and IMVT Related Press Releases
Go Back- Immunovant Announces Topline Results from Proof-of-Concept Study of IMVT-1402 in Cutaneous Lupus Erythematosus
- Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
- Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026
- Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
- Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
